Analysis – Page 69 – Goldea Capital

Parex Resources Positioned to Become Colombia’s Largest Independent Oil & Gas Producer, Provides Step-Change Guidance, Reports Q1 2026 Results, and Declares Q2 2026 Dividend

Written by Customer Service on May 12, 2026. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, May 12, 2026 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce that the Company is poised to become Colombia’s largest independent oil and gas producer and to provide new corporate guidance. Additionally, the Company reports its financial and operating results for the three-month period ended March 31, 2026, and the declaration of its Q2 2026 regular dividend of C$0.385 per share. All amounts herein are in United States Dollars (“USD”) unless otherwise stated. “Over the first half of 2026, Parex executed a series of strategic transactions that have positioned us to be Colombia’s largest independent E&P, while adding complementary assets that enhance scale, deepen the portfolio, and strengthen our platform profitability for long-term growth,” said Imad Mohsen,...

POET Technologies Announces Appointment of Sandeep Kumar as Chief Operating Officer

Written by Customer Service on May 12, 2026. Posted in Public Companies.

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (NASDAQ: POET), a leader in highly integrated optical engines and light sources for AI networks, today announced the appointment of Sandeep Kumar as Chief Operating Officer reporting to the Chief Executive Officer. Dr. Kumar’s appointment was effective as of Monday, May 11, 2026. Dr. Kumar was also named as an Officer of the Corporation. Dr. Sandeep Kumar is an experienced executive in the semiconductor industry. In his last position at Silicon Labs based in Austin, TX where he worked for over 18 years, he was Senior Vice President of Worldwide Operations. He has managed manufacturing teams, supply chain, planning, CAD, process engineering, package engineering, product and test engineering, quality assurance, failure...

Hub Group Files Form 12b-25 and Provides First Quarter 2026 Business Update

Written by Customer Service on May 12, 2026. Posted in Public Companies.

OAK BROOK, Ill., May 12, 2026 (GLOBE NEWSWIRE) — Hub Group, Inc. (Nasdaq: HUBG) today announced that it has filed a Notification of Late Filing on Form 12b-25 with the U.S. Securities and Exchange Commission (“SEC”) and will be delayed in filing its Form 10-Q for the quarter ended March 31, 2026. As previously disclosed, the Company was unable to timely file its Form 10-K for the year ended December 31, 2025. The delay in filing the Form 10-K has resulted in a corresponding delay in the preparation and completion of the Form 10-Q for the quarter ended March 31, 2026. The Company has also determined that it will restate its financial statements as of and for each of the years ended December 31, 2024 and 2023. This determination follows a review, conducted under the direction of the Audit Committee of the Board of Directors, that...

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson’s disease demonstrating reduction in endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – Presented ARV-6723 (HPK1 degrader) preclinical data at the American Associated of Cancer Research Annual meeting demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Initiated dosing with ARV-027 (polyQ-AR degrader) in Phase 1 healthy volunteer...

NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Conference call will be held today, Tuesday, May 12 at 9:00 am ET CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026. 1Q26 Financial HighlightsRevenues increased 80% year over year to $1.6M, reflecting the AMA Category I CPT® code assignment for Percutaneous Electrical Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payor coverage. Expanded gross margin by 200 basis points and improved operating loss by 24% year over year as more IB-Stim® devices were sold at full price due to the recently secured Category I CPT® Code. Cash...

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 Commercial readiness activities continue in anticipation of the potential commercial launch of OLCMOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. “As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,” said Shalabh Gupta, M.D., Chief Executive...

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026 Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Appointed Charles Morris, M.D. as Chief Medical Officer Current cash runway expected into second quarter of 2028 based on preliminary estimates, driven by previously announced underwritten offering with gross proceeds of $90 million WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage...

Premier American Uranium Commences Drilling at Cebolleta as Part of 2026 Metallurgical Testing

Written by Customer Service on May 12, 2026. Posted in Public Companies.

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR” or “Premier American Uranium” or the “Company”) (TSXV: PUR, OTCQB: PAUIF) is pleased to announce that drilling has commenced at its Cebolleta Uranium Project in New Mexico (“Cebolleta” or the “Project”), marking an important step in the Company’s 2026 work program focused on advancing metallurgical optimization and project economics. The drill program is designed to support a comprehensive metallurgical testing campaign, previously announced in a press release dated March 27, 2026, with core samples to be used in a 42-week laboratory program aimed at optimizing the uranium recovery assumptions contained in the 2025 Preliminary Economic Assessment (“2025 PEA”), as detailed below. 2026 Drilling Program HighlightsDrilling is underway with up to 16 PQ...

Genco Trading & Shipping Limited Sets the Record Straight on Diana’s False and Misleading Claims

Written by Customer Service on May 12, 2026. Posted in Public Companies.

Urges Shareholders to Vote “FOR” Genco’s Highly Qualified Board on the WHITE Proxy Card – and “WITHHOLD” on Diana’s Nominees For More Information Visit www.GencoDrivesSuperiorReturns.com NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today issued the following communication with important facts shareholders should know to protect their Genco investment. KNOW THE FACTS: Vote the WHITE Proxy Card Diana Shipping Inc. (“Diana”) has made numerous false, misleading and unsubstantiated claims as part of its hostile campaign to take over Genco on the cheap. Do NOT be fooled. Diana is making these statements to distract from the simple truth: Diana is trying to take...

Lithium Argentina Reports First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) today announced its first quarter 2026 results. Unless otherwise stated, results are presented in United States dollars on a 100% basis. Sam Pigott, Lithium Argentina’s CEO, commented: “Cauchari-Olaroz continues to deliver exceptional performance, sustaining production near design capacity for a second consecutive quarter while delivering first-quarter cash operating costs below $5,400 per tonne. This operational consistency is translating directly into cash flow, with the operation expected to convert over 90% of first-quarter EBITDA into cash in 2026. “Building on this foundation, the Stage 2 expansion at Cauchari-Olaroz is progressing well, and we intend to grow organically by leveraging...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals